Hepatocellular carcinoma in elderly patients: a concise review on systemic therapy with sorafenib

Giuseppe L, Alessandro V, Lonardi S, Luisa B, Ardi P, Valentina M, Gino C, Camil

Lombardi Giuseppe1, Vitale Alessandro2, Sara Lonar

1 Department of Clinical and Experimental Oncology

2015年

58-62

其他外文数据库

The treatment of hepatocellular carcinoma (HCC) in elderly patients is unclear. In particular, the efficacy and safety of sorafenib as a systemic treatment in these patients is still under debate. We performed a concise review of sorafenib therapy in this population. However, it is important to make any decisions on treatment for elderly patients with HCC through a multidisciplinary team that includes experts in the liver disease. Patients with good clinical conditions should be treated with sorafenib.。